As of 2024-12-13, the Relative Valuation of Ultragenyx Pharmaceutical Inc (RARE) is (167.08) USD. This relative valuation is based on P/E multiples. With the latest stock price at 48.86 USD, the upside of Ultragenyx Pharmaceutical Inc based on Relative Valuation is -442.0%.
The range of the Relative Valuation is (170.35) - (189.24) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 28.1x - 44.5x | 34.7x |
| Forward P/E multiples | 20.3x - 31.3x | 20.5x |
| Fair Price | (170.35) - (189.24) | (167.08) |
| Upside | -448.6% - -487.3% | -442.0% |
| Date | P/E |
| 2024-12-04 | -7.78 |
| 2024-12-03 | -7.71 |
| 2024-12-02 | -7.86 |
| 2024-11-29 | -7.87 |
| 2024-11-27 | -7.95 |
| 2024-11-26 | -7.82 |
| 2024-11-25 | -7.78 |
| 2024-11-22 | -7.80 |
| 2024-11-21 | -7.60 |
| 2024-11-20 | -7.66 |
| 2024-11-19 | -7.46 |
| 2024-11-18 | -7.23 |
| 2024-11-15 | -7.39 |
| 2024-11-14 | -7.87 |
| 2024-11-13 | -8.05 |
| 2024-11-12 | -7.90 |
| 2024-11-11 | -8.38 |
| 2024-11-08 | -8.32 |
| 2024-11-07 | -8.33 |
| 2024-11-06 | -8.35 |
| 2024-11-05 | -8.62 |
| 2024-11-04 | -8.43 |
| 2024-11-01 | -8.42 |
| 2024-10-31 | -8.42 |
| 2024-10-30 | -8.56 |
| 2024-10-29 | -8.72 |
| 2024-10-28 | -8.77 |
| 2024-10-25 | -8.89 |
| 2024-10-24 | -9.06 |
| 2024-10-23 | -9.03 |
| 2024-10-22 | -9.05 |
| 2024-10-21 | -9.00 |
| 2024-10-18 | -9.29 |
| 2024-10-17 | -9.38 |
| 2024-10-16 | -9.53 |
| 2024-10-15 | -9.44 |
| 2024-10-14 | -9.28 |
| 2024-10-11 | -9.10 |
| 2024-10-10 | -8.90 |
| 2024-10-09 | -8.82 |
| 2024-10-08 | -8.80 |
| 2024-10-07 | -8.66 |
| 2024-10-04 | -8.89 |
| 2024-10-03 | -8.86 |
| 2024-10-02 | -9.18 |
| 2024-10-01 | -9.33 |
| 2024-09-30 | -9.18 |
| 2024-09-27 | -8.99 |
| 2024-09-26 | -9.12 |
| 2024-09-25 | -9.38 |